CHYMOCIP
Brand:
CHYMOCIP
Manufacturer:
CIPLA
Manufacturer Details
CIPLA
Compositions:
Chymotrypsin 1000000 AU e.c tablets,
|
Strength
|
Rate
|
Packing Style
|
|
1000000 AU e.c.
|
364.69
|
20s ec tablets
|
List of Related Indications:
- Adjun thear in inflamm condit
List Of Drugs:
- Chymotrypsin - Other derivatives- (FDC List) (Sep 1971)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Reports not available.
Indication:
Enzymatic zonulysis for intracapsular extraction
FIXED DOSE COMBINATIONS APPROVED BY DCG(I)
FROM JANUARY 1961 TILL NOVEMBER 2014
Name of Drug Indication Date of Approval
Alpha chymotriptin 60mg + Sept -71
Ethyl nicotinate 200mg per 20gm ointment
Adverse Reaction:
Severe allergic reactions following intramuscular admin.
Ophthalmological -Increased intraoccular pressure corneal odema, striation and uvetitis following opthalmic use.
Contra-Indications:
Hypersentivity to or any component of the preparation
High vitreous pressure; gaping incisional wound,
congenital catarats, patients less than 20 years old due to probable lens-vitreous adhesion not responsive to alpha - chymotrypsin lysis
Dosages/ Overdosage Etc:
Indications:
Enzymatic zonulysis for intracapsular extraction
Dosage-
1 tab 4 times daily before meals
Pharmacology/ Pharmacokinetics:
Pharmacology:
Chymotrypsin is a proteolytic enzyme. The principal proteolytic effect is exerted by splitting of peptide bonds of amino acids in zonular fibers and ocular tissues.
Pharmacokinetics:
Destruction of the equatorial pericapsular membrane of the lens occurs in 5 minutes. Zolar fibers are lysed within 10 to 15 minutes of application; complete lysis of the entire membrane occurs in 30 minutes.
